SORRENTO THERAPEUTICS, INC. (NASDAQ:SRNE) Files An 8-K Financial Statements and Exhibits
Item 9.01, which was not previously filed with the Initial Form
8-K and which is
permitted to be filed by amendment no later than 71 calendar days
after the date on which the Initial Form 8-K was required to be
filed. Except as stated in this Explanatory Note, no other
information contained in the Initial Form 8-K is changed.
Item9.01.Financial
Statements and Exhibits.
(a) Financial
statements of businesses acquired.
The financial
statements required by Item 9.01(a) of Form 8-K are filed as
Exhibit 99.2 and Exhibit 99.3 to this Amendment No.1 and are
incorporated herein by reference.
(b) Pro forma
financial information.
The pro forma
financial information required by Item 9.01(b) of Form 8-K is
filed as Exhibit 99.4 to this Amendment No.1 and is incorporated
herein by reference.
(d)
Exhibits.
| 23.1 |
Consent of BDO USA, LLP, independent registered public accounting firm of Scilex Pharmaceuticals Inc. |
|
| 99.2 |
Unaudited condensed financial statements of Scilex Pharmaceuticals Inc. as of September30, 2016 and for the three and nine months ended September30, 2016 and 2015. |
|
| 99.3 |
Audited financial statements of Scilex Pharmaceuticals Inc. as of and for the years ended December31, 2015 and 2014. |
|
| 99.4 |
Unaudited pro forma condensed combined financial information of Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals Inc. for the nine months ended September30, 2016 and the year ended December31, 2015. |
About SORRENTO THERAPEUTICS, INC. (NASDAQ:SRNE)
Sorrento Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, acquisition, development and commercialization of drug therapeutics. Its primary therapeutic focus is oncology, including the treatment of chronic cancer pain. It is also developing therapeutic products for other indications, including immunology and infectious diseases. Its products in the pipeline include Chimeric Antigen Receptor-T Cell (CAR-T) programs, resiniferatoxin (RTX), and biosimilar/biobetter antibodies clinical development programs. Its pipeline also includes preclinical fully human therapeutic monoclonal antibodies (mAbs), including biosimilars/biobetters, fully human anti-PD-L1 and anti-PD-1 checkpoint inhibitors derived from its G-MAB library platform, antibody drug conjugates (ADCs), bispecific antibodies (BsAbs), as well as CAR-T and Chimeric Antigen Receptor Natural Killer (NK) cells (CAR. NK) for adoptive cellular immunotherapy. SORRENTO THERAPEUTICS, INC. (NASDAQ:SRNE) Recent Trading Information
SORRENTO THERAPEUTICS, INC. (NASDAQ:SRNE) closed its last trading session up +0.12 at 5.43 with 59,960 shares trading hands.
